Fariborz Kamal, Ph.D., serves as the Chief Operating Officer & President at 4D Molecular Therapeutics Inc., a position that underscores his extensive experience and leadership in the biotechnology sector. Dr. Kamal's professional journey is marked by significant contributions to the field of gene therapy and drug development. Before joining 4D Molecular Therapeutics, he held pivotal roles at several prominent biotech companies, including Sangamo Therapeutics, where he served as Senior Vice President and Chief Business Officer. His tenure at Sangamo was characterized by his strategic oversight of business development, which included forging key partnerships that advanced the company's gene therapy programs. Dr. Kamal's academic background is equally robust, holding a Ph.D. in Biochemistry from the University of California, Davis. His early career included postdoctoral research at Stanford University, where he delved into the molecular mechanisms of cancer and other diseases. This foundational research has informed his approach to developing innovative therapies at 4D Molecular Therapeutics. As COO and President, Dr. Kamal is instrumental in steering the company's operational strategies and ensuring the successful execution of its clinical and research initiatives. His leadership is pivotal in advancing the company's mission to develop transformative genetic medicines for large market diseases. At 4D Molecular Therapeutics, Dr. Kamal's role extends beyond operational management; he is a key figure in shaping the company's strategic direction. Under his guidance, the company has made significant strides in its clinical pipeline, particularly in the development of novel AAV vectors designed to deliver therapeutic genes with high precision and efficiency. His ability to blend scientific expertise with business acumen has been crucial in navigating the complex landscape of gene therapy development. Dr. Kamal's vision and leadership continue to drive 4D Molecular Therapeutics toward its goal of revolutionizing treatment options for patients worldwide.